Chronic transfusion therapy (CTT) for sickle cell disease (SCD) reduces disease morbidity by suppressing the amount of circulating hemoglobin S (HbS)-containing red blood cells (RBC). The effectiveness of CTT depends on the rate of RBC clearance. Glucose-6-phosphate dehydrogenase (G6PD) deficient donor RBC may exhibit increased hemolysis, but it is unknown if transfusion of these units results in less effective transfusion outcomes in SCD. Children with SCD on CTT were followed prospectively for multiple transfusions. G6PD activity of transfused units was measured prior to expiration date. HbA clearance (DHbA) was calculated as the difference of estimated posttransfusion HbA to the pretransfusion HbA of the subsequent transfusion episode. Sixty-two patients received 388 transfusions. Of 755 RBC units, 687 (91%) had normal G6PD (>60% activity), 38 (5%) had moderately low G6PD (10-60% activity), and 30 (4%) had severely low G6PD (<10% activity). Of 358 evaluable transfusions, 54 (15%) included 1 G6PD deficient units, and 22 (6%) had 1 severely deficient units. The proportion of the transfusion episode consisting of G6PD deficient units was associated with increased DHbA for all G6PD deficient units (P 5 .05) and for severely G6PD deficient units (P 5 .0070). In multivariate mixed effects modeling, DHbA was positively associated with severely G6PD deficient units (P 5 .0074) and RBC alloimmunization (P 5 .03) and negatively associated with recipient splenectomy (P 5 .015). Higher DHbA was associated with higher HbS and reticulocyte counts at the subsequent transfusion episode. In conclusion, G6PD deficient RBC transfusions may have shorter in vivo survival and adversely affect the suppression of sickle erythropoiesis.
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| I N TR ODU C TI ON
Chronic transfusion therapy (CTT) for sickle cell disease (SCD) is an essential treatment for the prevention of severe sickle complications such as stroke. Red blood cell (RBC) transfusions to individuals with SCD have unique considerations, including the selection of units that are hemoglobin S (HbS) negative and RBC antigen matching for C/c, E/e, K, and potentially other antigens due to the high prevalence of alloimmunization in SCD. 1 To meet these antigen matching requirements, donors who are phenotypically matched for SCD patients are disproportionately of African descent, 2, 3 thus are more likely to have glucose-6-phosphate dehydrogenase (G6PD) deficiency or hemoglobin variants other than HbS. 
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G6PD deficiency is the most common enzyme deficiency worldwide, affecting an estimated 5% of the world population, or 400 million individuals. 6 G6PD deficiency is an X-linked inherited disorder that includes a large number of allelic variants, such that variants may be classified as severely deficient (<10% enzyme activity) or moderately deficient (10%-60% activity). 7 The prevalence of G6PD deficiency is highest in sub-Saharan Africa and the Middle East, with male summary prevalence estimates of 8.5% and 7.2%, respectively. 6 The vast majority of individuals with G6PD deficiency are asymptomatic, thus they may be unaware of their G6PD deficiency status and are as likely to be a blood donor as a G6PD replete individual. G6PD is the rate-limiting enzyme of the pentose phosphate pathway, generating reduced nicotinamide-adenine dinucleotide phosphate, which is essential to protecting RBC from oxidative stress. In G6PD deficiency, reactive oxygen species can accumulate, resulting in episodes of intravascular, and extravascular hemolysis.
In vitro data of stored RBC units from G6PD deficient donors suggests that G6PD deficient RBC have increased reactive oxygen species accumulation and hemolysis when subjected to conditions simulating transfusion. 8 To date, there remains limited evidence regarding the effects of transfusion of G6PD deficient blood; however studies indicate that G6PD deficient RBC transfusions may be associated with insufficient rise in hemoglobin posttransfusion in children and may promote hemolysis in neonatal recipients. 9 The World Health Organization recommends that G6PD deficient donors are acceptable unless there is history of clinical hemolysis; in contrast, blood from these donors is considered not acceptable for intrauterine and neonatal exchange transfusion or for transfusion to recipients with G6PD deficiency. 7 Despite this, blood donors are not routinely screened for G6PD deficiency, thus little is known about the effects of these units on transfusion outcomes in children with SCD.
The primary hematologic goal of CTT in SCD is the suppression of erythropoiesis, thus the effectiveness of CTT is monitored by pretransfusion levels of HbS and reticulocytes. The survival of transfused RBC affects the suppression of erythropoiesis and thus sickling, hemolysis, and vaso-occlusion of recipient erythrocytes. In this study, we sought to examine the effect of donor G6PD deficiency on the clearance of HbA in children with SCD on CTT. 
| M E TH ODS

| G6PD testing
Segments of donor units, when available, were tested for G6PD activity level no later than their date of expiration. The quantitative G6PD
assay (Trinity Biotech, Berkeley Heights, New Jersey) was performed as previously described. 4 G6PD activity was expressed as units of enzyme activity per gram of hemoglobin (U/g Hb). G6PD deficiency was defined as activity <60% of the normal mean (<3.9 U/g Hb), while severe G6PD deficiency was defined as activity <10% of the normal mean for stored RBC units (<1.3 U/g Hb). 4 The G6PD-deficient ratio 
| Hemoglobin A clearance (DHbA) calculation
The loss of HbA (DHbA) from the end of a transfusion episode to the end of the transfusion cycle (i.e., immediately prior to the next scheduled transfusion) was calculated as using the following equations. The amount of donor Hb was expressed as "HbA" which is the sum of 
| Statistical analysis
The association of DHbA with G6PD deficient transfusion was assessed several ways, utilizing mixed modeling to account for repeated meas- Of the 388 transfusion episodes, 6 were excluded because 1 unit in the transfusion lacked G6PD testing results, and 24 were excluded for lack of DHbA estimation (due to missing pretransfusion HbA measurement). Therefore, a total of 358 transfusion episodes (687 units)
were analyzed to assess the association of G6PD status with DHbA. In univariate mixed effects analysis of DHbA to the G6PD-deficient ratio, DHbA was greater in transfusions with higher overall G6PD-deficient ratios, including both moderate and severe G6PD deficient units (P 5 .05). When exclusively comparing severe G6PD deficient transfusions to nonsevere G6PD deficient transfusions, the positive association of DHbA with G6PD-deficient ratio was stronger (P 5 .0070). In multivariate linear mixed effects modeling (Table 1) HbS levels >30% may be associated with progressive cerebrovascular disease and stroke despite CTT. [12] [13] [14] This is the first study to examine the prevalence of G6PD deficient units provided to children with SCD during CTT. Previously, Francis et al.
showed a low prevalence of G6PD deficiency among randomly selected RBC units (0.3%) but a much higher prevalence of 12.3% among D 1 C-E-RBC units, which is the most common Rh phenotype of SCD patients. 15 Our study showed a 9% prevalence of G6PD deficiency among units provided to SCD patients; however given that most patients require more than 1 RBC unit to provide sufficient transfusion volume, the prevalence of G6PD deficient transfusion episodes was 15%. Thus, as G6PD deficient transfusions to SCD patients are common events, caution must be exercised in considering whether these RBC units are deleterious or benign in SCD. Individuals on CTT who have poor suppression of HbS levels may be candidates for whom G6PD deficient transfusions should be avoided, to maximize survival of transfused RBCs. Additionally, in keeping with the WHO recommendations for transfusion of G6PD deficient units, consideration should be given toward testing the G6PD status of all patients on CTT to avoid transfusion of G6PD deficient units to these patients. 16 In this study, the storage age of RBC units was not associated with differences in HbA clearance post transfusion; however this study was not powered to examine the impact of older units on HbA decline. The majority of units in this study had a storage duration of less than 3 weeks, while only 5% of units had a storage duration of 5 weeks or longer, thus the impact of the extremes of storage duration cannot be evaluated by this study. Studies of RBC metabolomics have shown declines in glutathione and other metabolites involved in cellular energy and antioxidant defense pathways in RBC stored up to 42 days. 17 Additionally, in a study of autologous transfusion to healthy adults, storage duration up to 6 weeks was associated with extravascular 
